US Stock MarketDetailed Quotes

ATXS Astria Therapeutics Inc

Watchlist
  • 6.240
  • -0.200-3.11%
Trading Mar 3 12:28 ET
352.15MMarket Cap-2.86P/E (TTM)

About Astria Therapeutics Inc Company

Astria Therapeutics, Inc. engages in the discovery, development, and commercialization of novel therapeutics. Its lead product candidate is STAR-0215, which is intended to treat Hereditary Angioedema, a rare genetic disorder characterized by severe, recurrent, unpredictable, painful, and sometimes life-threatening swelling in the face, limbs, abdomen, and airway. The company was founded by Michael R. Jirousek, Jill C. Milne and Steven E. Shoelson on June 26, 2008 and is headquartered in Boston, MA.

Company Profile

SymbolATXS
Company NameAstria Therapeutics Inc
Listing DateJun 25, 2015
Issue Price12.00
Founded2008
CEODr. Jill C. Milne, PhD
MarketNASDAQ
Employees59
Fiscal Year Ends12-31
Address22 Boston Wharf Road,10th floor
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02210
Phone1-617-349-1971

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Jill C. Milne, PhD
  • Director, President and Chief Executive Officer
  • 2.96M
  • Andrea Matthews
  • Chief Business Officer
  • --
  • Noah Clauser
  • Chief Financial Officer, Principal Accounting Officer and Treasurer
  • 1.35M
  • Dr. Christopher Morabito, M.D.
  • Chief Medical Officer
  • 1.32M
  • Benjamin Harshbarger
  • Chief Legal Officer
  • --
  • Andrew Komjathy
  • Chief Commercial Officer
  • --
  • Kenneth M. Bate
  • Chairman of the Board
  • 194.17K
  • Dr. Sunil Agarwal, M.D.
  • Director
  • --
  • Michael D. Kishbauch
  • Independent Director
  • 157.67K
  • Gregg Anthony Lapointe, C.P.A.,M.B.A.
  • Independent Director
  • 163.67K
  • Frederick C. Callori
  • Independent Director
  • 152.67K
  • Hugh M. Cole
  • Independent Director
  • 151.17K
  • Dr. Jonathan Violin, M.B.A.,PhD
  • Independent Director
  • 158.67K
  • Dr. Joanne T. Beck, PhD
  • Independent Director
  • 256.17K

Trending Stocks

Top Gaining Chinese Stocks Top Gaining Chinese Stocks
Unlock Now
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Tesla's earnings caused fluctuations, what's your market outlook?
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More